The UK's 'Golden Triangle' of London, Oxford and Cambridge has enlisted Boston's biotech super cluster as it first international partner. The UK's three leading life sciences and healthcare hubs recently formed the Golden Triangle Partnership (GTP), an informal coalition between the Oxfordshire Bioscience Network, Cambridge's biotech trade association ERBI and the London Biotechnology Network, which represents around 80% of the UK's life science and healthcare business activity. The aim is to form a critical mass comparable to international bioclusters with which to attract global partnerships. “We decided to break down barriers and work together to create more business opportunities for our members,” explains Harriet Fear, CEO of ERBI. The GTP will sign a memorandum of understanding with the Massachusetts Biotech Council (MBC) at the MassBio Investors Forum on October 6. The UK's GTP sees the alliance with Boston's MBC as a mutually beneficial deal, providing privileges to its own member companies and those in the US, including reduced rates for partnering events and enhanced access to investor slots. The reaction from other UK regions, like Scotland, has been positive. Fear says, “Common sense suggests there is likely to be a knock-on effect, raising the profile of the whole of the UK.”